Subsequent evaluation of eftozanermin alfa at three concurrent (non-randomized) dose levels up to 7.5 mg/kg QW in dose-optimization cohorts that included patients with PaCA and KRAS-mutated CRC confirmed the safety findings of the dose-escalation cohort, and permitted an expanded evaluation of eftozanermin alfa safety, pharmacokinetics, and pharmacodynamics. The gene discussed is KRAS; the disease is colorectal carcinoma.